Margrit Wiesendanger
Rheumatology · New York, NYNPI 1922200245
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,255 of the $4,580 with a category attached, or 92.9%. E.r. Squibb & Sons, L.L.C. accounts for 92.9% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $4,440, more than ten times the $22 reported in 2021.
Across 7 payments — averaging $654.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- AstraZeneca$195
- Impedimed, Inc.$74
- Amgen$35
- Novartis$22
Across 17 payments — averaging $58,956 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$704K
- E.r. Squibb & Sons, L.L.C.$299K
What the payments were for
- Consulting fees$4,25593%
- Food & beverage$3257%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $4,255 |
| AstraZeneca | 2 | $195 |
| Impedimed, Inc. | 1 | $74 |
| Amgen | 1 | $35 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$111
How this compares
$4,580 in reported general payments places this provider in the 60th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 64 | $405,013 |
| Humira(Cf) PenAdalimumab | 56 | $358,272 |
| Orencia ClickjectAbatacept | 39 | $230,424 |
| XeljanzTofacitinib Citrate | 33 | $215,579 |
| Cosentyx Sensoready PenSecukinumab | 16 | $156,716 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $130,067 |
| RinvoqUpadacitinib | 20 | $121,635 |
| KevzaraSarilumab | 25 | $106,050 |
| Cosentyx SyringeSecukinumab | 12 | $83,216 |
| BenlystaBelimumab | 18 | $79,836 |
| Actemra ActpenTocilizumab | 16 | $67,664 |
| ActemraTocilizumab | 13 | $30,678 |
| RasuvoMethotrexate/Pf | 32 | $17,125 |
| Mycophenolic AcidMycophenolate Sodium | 30 | $12,399 |
| Mycophenolate Mofetil | 45 | $7,398 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.